Related Experiment Videos
[Therapy concepts in chronic hepatitis C]
1Medizinische Abteilung, St Claraspital, Basel.
Schweizerische Medizinische Wochenschrift
|January 15, 1999
Summary
Patients with normal liver enzymes and minimal liver damage should not undergo antiviral therapy. Those with significant liver inflammation or fibrosis benefit most from combination therapy, particularly within clinical trials.
Area of Science:
- Hepatology
- Virology
- Internal Medicine
Context:
- Chronic hepatitis C (HCV) management requires accurate risk stratification.
- Liver biopsy remains crucial for assessing disease activity and fibrosis stage.
- Alcohol consumption exacerbates HCV progression.
Purpose:
- To define treatment strategies for chronic hepatitis C based on histologic findings.
- To evaluate the efficacy of different antiviral regimens.
- To identify optimal patient candidates for clinical trials.
Summary:
- Patients with normal transaminases and no significant liver biopsy findings have a low risk of progression and poor response to current antiviral treatments.
- Significant histologic activity or advanced fibrosis indicates a high risk for cirrhosis, especially with concurrent alcohol consumption.
- Combination therapy (interferon plus ribavirin) significantly improves sustained virological remission rates (2-6 times higher than interferon alone), with potential further enhancement via high-dose, daily interferon (inductive dosing).
Impact:
- Guides clinical decision-making for hepatitis C treatment initiation.
- Highlights the importance of liver biopsy in treatment selection.
- Emphasizes the superior efficacy of combination therapy for advanced disease.
- Recommends enrollment in clinical trials for optimal management of significant chronic hepatitis C.